NunaBio key facts
as of Oct 2026- Developer of chemical and biological technologies and products designed to conduct research and development into cell-free DNA synthesis and manufacture DNA.
- NunaBio is valued at approximately $16.1M as of Oct 2026 (last reported valuation).
- It has raised $11.3M; the latest was Later Stage VC ($7.6M) in Mar 2026.
- Notable investors include Innovate UK, Ascension, European Regional Development Fund (Brandenburg), Northstar Ventures, Ascension Ventures — 10 tracked in total.
- Status: Privately Held (backing).
NunaBio's last reported valuation, Mar 2026. Nothing priced has surfaced since.
- ·Watch NunaBio: the Monday email on marks, rounds and moves
NunaBio funding rounds
No funding rounds for NunaBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
NunaBio valuation
NunaBio's last reported valuation was $16.1 million in Mar 2026. No priced round, secondary trade or fund mark has surfaced since.
NunaBio investors
10 investors are on record for NunaBio, including Innovate UK, Ascension, European Regional Development Fund (Brandenburg) and Northstar Ventures.
About NunaBio
Developer of chemical and biological technologies and products designed to conduct research and development into cell-free DNA synthesis and manufacture DNA. The company offers a range of long and short deoxyribonucleic acid products from microgram through to gram scale, cell therapies, vaccines, diagnostics, gene therapies, and deoxyribonucleic acid biosensing and consumables, enabling healthcare professionals to treat patients using advanced therapeutic methods.
- Sector
- Healthcare
- HQ
- Newcastle Upon Tyne, United Kingdom
- Founded
- 2012
- Employees
- 21
- Website
- nunabio.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.